Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RCAX | Tidal Trust II - Defiance Daily Target 2x Long Rcat ETF | $18.00 | $4.83 | 36.70% | 491.7K | - | $11.66$22.31 |
| USGO | U.s. GoldMining | $15.34 | $3.30 | 27.36% | 597.1K | $160M | $7.42$17.98 |
| EMAT | Evolution Metals & Technologies | $10.14 | $2.17 | 27.23% | 284.5K | $23M | $5.50$24.37 |
| RLYB | Rallybio | $9.54 | $2.00 | 26.52% | 2.8M | $40M | $1.76$10.70 |
| ALMU | Aeluma | $19.42 | $3.95 | 25.53% | 46K | $279M | $5.79$25.88 |
| MGN | Megan | $2.50 | $0.50 | 25.00% | 274.2K | $33M | $1.00$8.63 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $3.00 | $0.60 | 24.79% | 29.9M | - | $0.95$20.92 |
| ASTH | Astrana Health | $25.37 | $5.04 | 24.79% | 54.4K | $1.0B | $18.08$34.80 |
| LSE | Leishen Energy | $5.72 | $1.12 | 24.35% | 104.2K | $78M | $3.80$14.99 |
| AAOI | Applied Optoelectronics | $102.79 | $18.56 | 22.04% | 857.4K | $5.8B | $9.71$110.00 |
| MVO | Mv Oil Trust | $2.52 | $0.45 | 21.74% | 21.1K | $24M | $0.97$6.60 |
| CGEN | Compugen | $2.20 | $0.39 | 21.27% | 1.2M | $169M | $1.13$2.38 |
| PURR | Hyperliquid Strategies | $4.94 | $0.86 | 20.96% | 5.7M | $506M | $3.01$5.78 |
| OCUL | Ocular Therapeutix | $10.68 | $1.74 | 19.46% | 315.9K | $1.9B | $5.79$16.44 |
| RCAT | Red Cat | $13.87 | $2.22 | 19.06% | 26.1M | $1.4B | $4.58$18.02 |
| LASR | nLIGHT | $66.00 | $9.81 | 17.46% | 2.8M | $3.1B | $6.20$67.67 |
| RCUS | Arcus Biosciences | $23.81 | $3.44 | 16.89% | 45.8K | $2.5B | $6.50$26.40 |
| HYPD | Hyperion DeFi | $3.29 | $0.47 | 16.49% | 281.1K | $23M | $0.85$17.18 |
| JFB | Jfb Construction | $17.66 | $2.49 | 16.41% | 4.2K | $96M | $3.39$35.10 |
| SYPR | Sypris Solutions | $3.44 | $0.48 | 16.22% | 166.7K | $68M | $1.42$4.74 |
| CHNR | China Natural Resources | $3.70 | $0.47 | 14.55% | 135K | $4.0M | $3.16$8.20 |
Related Articles
Featured Article
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
George Budwell, PhD|Jan 3, 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.
This Exciting Biopharma Could Earn You 55% in 12 Months
Jeffrey Little|Aug 22, 2021
When patients see more clearly, so too should investors.
4 Reasons I Just Bought Ocular Therapeutix Stock
Cory Renauer|Aug 21, 2021
This company's drug delivery technology just isn't getting the appreciation it deserves right now.
Why Arcus Biosciences' Big Reveal Wasn't Very Exciting
Cory Renauer|Jun 25, 2021
No news from Arcus Biosciences is bad news for the company and other industry heavyweights.
Can Ocular Therapeutix Reach Its Full Potential?
Brian Orelli, PhD and Keith Speights|Apr 1, 2021
The biotech has a ways to go.
![Can_Ocular_Therapeutix_Reach_Its_Full_Potential[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619459%2Fcan_ocular_therapeutix_reach_its_full_potential1.jpg&w=384&op=resize)
3 Top Healthcare Stocks to Buy Now
Cory Renauer|Feb 17, 2021
Find out how shares of these disruptive businesses could make you rich.
3 Reasons to Buy Ocular Therapeutix Stock Right Now
Cory Renauer|Feb 16, 2021
There are a few reasons this could be the best biotech stock you can buy at the moment.
3 Top 5G Stocks to Buy in September
5G networks have made nationwide debuts, but these hardware stocks could have the most to gain.
Gilead Sciences Signs $2 Billion Partnership with Arcus Biosciences
Jim Crumly|May 27, 2020
The deal gives Gilead access to a new pipeline of potential cancer immunotherapies.
2 Top Biotech Picks for May
Zhiyuan Sun|May 20, 2020
Here are the hottest companies coming up in the biotech sector.
